Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals

for the Worldwide Esophageal Cancer Collaboration Investigators

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We report analytic and consensus processes that produced recommendations for pathologic stage groups (pTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration provided data for 22,654 patients with epithelial esophageal cancers; 13,300 without preoperative therapy had pathologic assessment after esophagectomy or endoscopic treatment. Risk-adjusted survival for each patient was developed using random survival forest analysis to identify data-driven pathologic stage groups wherein survival decreased monotonically with increasing group, was distinctive between groups, and homogeneous within groups. The AJCC Upper GI Task Force, by smoothing, simplifying, expanding, and assessing clinical applicability, produced consensus pathologic stage groups. For pT1-3N0M0 squamous cell carcinoma (SCC) and pT1-2N0M0 adenocarcinoma, pT was inadequate for grouping; subcategorizing pT1 and adding histologic grade enhanced staging; cancer location improved SCC staging. Consensus eliminated location for pT2N0M0 and pT3N0M0G1 SCC groups, and despite similar survival, restricted stage 0 to pTis, excluding pT1aN0M0G1. Metastases markedly reduced survival; pT, pN, and pM sufficiently grouped advanced cancers. Stage IIA and IIB had different compositions for SCC and adenocarcinoma, but similar survival. Consensus stage IV subgrouping acknowledged pT4N+ and pN3 cancers had poor survival, similar to pM1. Anatomic pathologic stage grouping, based on pTNM only, produced identical consensus stage groups for SCC and adenocarcinoma at the cost of homogeneity in early groups. Pathologic staging can neither direct pre-treatment decisions nor aid in prognostication for treatment other than esophagectomy or endoscopic therapy. However, it provides a clean, single therapy reference point for esophageal cancer.

Original languageEnglish (US)
Pages (from-to)897-905
Number of pages9
JournalDiseases of the Esophagus
Volume29
Issue number8
DOIs
StatePublished - Nov 1 2016

Fingerprint

Esophagogastric Junction
Esophageal Neoplasms
Squamous Cell Carcinoma
Survival
Adenocarcinoma
Esophagectomy
Neoplasms
Therapeutics
Decision Support Techniques
Neoplasm Staging
Advisory Committees
Survival Analysis
Neoplasm Metastasis

Keywords

  • epidemiology
  • esophagectomy
  • esophagogastric junction
  • oncology

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. / for the Worldwide Esophageal Cancer Collaboration Investigators.

In: Diseases of the Esophagus, Vol. 29, No. 8, 01.11.2016, p. 897-905.

Research output: Contribution to journalArticle

@article{7574bb57ecca41a1bf516ad29cebe60b,
title = "Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals",
abstract = "We report analytic and consensus processes that produced recommendations for pathologic stage groups (pTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration provided data for 22,654 patients with epithelial esophageal cancers; 13,300 without preoperative therapy had pathologic assessment after esophagectomy or endoscopic treatment. Risk-adjusted survival for each patient was developed using random survival forest analysis to identify data-driven pathologic stage groups wherein survival decreased monotonically with increasing group, was distinctive between groups, and homogeneous within groups. The AJCC Upper GI Task Force, by smoothing, simplifying, expanding, and assessing clinical applicability, produced consensus pathologic stage groups. For pT1-3N0M0 squamous cell carcinoma (SCC) and pT1-2N0M0 adenocarcinoma, pT was inadequate for grouping; subcategorizing pT1 and adding histologic grade enhanced staging; cancer location improved SCC staging. Consensus eliminated location for pT2N0M0 and pT3N0M0G1 SCC groups, and despite similar survival, restricted stage 0 to pTis, excluding pT1aN0M0G1. Metastases markedly reduced survival; pT, pN, and pM sufficiently grouped advanced cancers. Stage IIA and IIB had different compositions for SCC and adenocarcinoma, but similar survival. Consensus stage IV subgrouping acknowledged pT4N+ and pN3 cancers had poor survival, similar to pM1. Anatomic pathologic stage grouping, based on pTNM only, produced identical consensus stage groups for SCC and adenocarcinoma at the cost of homogeneity in early groups. Pathologic staging can neither direct pre-treatment decisions nor aid in prognostication for treatment other than esophagectomy or endoscopic therapy. However, it provides a clean, single therapy reference point for esophageal cancer.",
keywords = "epidemiology, esophagectomy, esophagogastric junction, oncology",
author = "{for the Worldwide Esophageal Cancer Collaboration Investigators} and Rice, {T. W.} and H. Ishwaran and Hofstetter, {W. L.} and Kelsen, {D. P.} and C. Apperson-Hansen and Blackstone, {E. H.} and Chen, {Ken N.} and Rice, {Thomas W.} and Blackstone, {Eugene H.} and Carolyn Apperson-Hansen and Wijnhoven, {Bas P L} and {van Lanschot}, Jan and Sjoerd Lagarde and Liu, {Jun Feng} and Scott, {Walter J.} and Donna Edmondson and Riette Burger and Davies, {Andrew R.} and Janine Zylstra and R{\"a}s{\"a}nen, {Jari V.} and Salo, {Jarmo A.} and Yvonne Sundstrom and Kenneth Kesler and D'Journo, {Xavier B.} and Kesler, {Kenneth A.} and Hofstetter, {Wayne L.} and Arlene Correa and Swisher, {Stephen G.} and Allen, {Mark S.} and Denlinger, {Chad E.} and Rusch, {Valerie W.} and Smithers, {B. Mark} and David Gotley and Andrew Barbour and Iain Thomson and Griffin, {S. Michael} and Jon Shenfine and Schipper, {Paul H.} and Hunter, {John G.} and Allum, {William H.} and {(Vincent) Fang}, Wentao and Darling, {Gail E.} and Lerut, {Tony E M R} and Nafteux, {Phillipe R.} and {van Hillegersberg}, Richard and Cerfolio, {Robert J.} and Luis Durand and {De Ant{\'o}n}, Roberto and Ferguson, {Mark K.} and Simon Law",
year = "2016",
month = "11",
day = "1",
doi = "10.1111/dote.12533",
language = "English (US)",
volume = "29",
pages = "897--905",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals

AU - for the Worldwide Esophageal Cancer Collaboration Investigators

AU - Rice, T. W.

AU - Ishwaran, H.

AU - Hofstetter, W. L.

AU - Kelsen, D. P.

AU - Apperson-Hansen, C.

AU - Blackstone, E. H.

AU - Chen, Ken N.

AU - Rice, Thomas W.

AU - Blackstone, Eugene H.

AU - Apperson-Hansen, Carolyn

AU - Wijnhoven, Bas P L

AU - van Lanschot, Jan

AU - Lagarde, Sjoerd

AU - Liu, Jun Feng

AU - Scott, Walter J.

AU - Edmondson, Donna

AU - Burger, Riette

AU - Davies, Andrew R.

AU - Zylstra, Janine

AU - Räsänen, Jari V.

AU - Salo, Jarmo A.

AU - Sundstrom, Yvonne

AU - Kesler, Kenneth

AU - D'Journo, Xavier B.

AU - Kesler, Kenneth A.

AU - Hofstetter, Wayne L.

AU - Correa, Arlene

AU - Swisher, Stephen G.

AU - Allen, Mark S.

AU - Denlinger, Chad E.

AU - Rusch, Valerie W.

AU - Smithers, B. Mark

AU - Gotley, David

AU - Barbour, Andrew

AU - Thomson, Iain

AU - Griffin, S. Michael

AU - Shenfine, Jon

AU - Schipper, Paul H.

AU - Hunter, John G.

AU - Allum, William H.

AU - (Vincent) Fang, Wentao

AU - Darling, Gail E.

AU - Lerut, Tony E M R

AU - Nafteux, Phillipe R.

AU - van Hillegersberg, Richard

AU - Cerfolio, Robert J.

AU - Durand, Luis

AU - De Antón, Roberto

AU - Ferguson, Mark K.

AU - Law, Simon

PY - 2016/11/1

Y1 - 2016/11/1

N2 - We report analytic and consensus processes that produced recommendations for pathologic stage groups (pTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration provided data for 22,654 patients with epithelial esophageal cancers; 13,300 without preoperative therapy had pathologic assessment after esophagectomy or endoscopic treatment. Risk-adjusted survival for each patient was developed using random survival forest analysis to identify data-driven pathologic stage groups wherein survival decreased monotonically with increasing group, was distinctive between groups, and homogeneous within groups. The AJCC Upper GI Task Force, by smoothing, simplifying, expanding, and assessing clinical applicability, produced consensus pathologic stage groups. For pT1-3N0M0 squamous cell carcinoma (SCC) and pT1-2N0M0 adenocarcinoma, pT was inadequate for grouping; subcategorizing pT1 and adding histologic grade enhanced staging; cancer location improved SCC staging. Consensus eliminated location for pT2N0M0 and pT3N0M0G1 SCC groups, and despite similar survival, restricted stage 0 to pTis, excluding pT1aN0M0G1. Metastases markedly reduced survival; pT, pN, and pM sufficiently grouped advanced cancers. Stage IIA and IIB had different compositions for SCC and adenocarcinoma, but similar survival. Consensus stage IV subgrouping acknowledged pT4N+ and pN3 cancers had poor survival, similar to pM1. Anatomic pathologic stage grouping, based on pTNM only, produced identical consensus stage groups for SCC and adenocarcinoma at the cost of homogeneity in early groups. Pathologic staging can neither direct pre-treatment decisions nor aid in prognostication for treatment other than esophagectomy or endoscopic therapy. However, it provides a clean, single therapy reference point for esophageal cancer.

AB - We report analytic and consensus processes that produced recommendations for pathologic stage groups (pTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration provided data for 22,654 patients with epithelial esophageal cancers; 13,300 without preoperative therapy had pathologic assessment after esophagectomy or endoscopic treatment. Risk-adjusted survival for each patient was developed using random survival forest analysis to identify data-driven pathologic stage groups wherein survival decreased monotonically with increasing group, was distinctive between groups, and homogeneous within groups. The AJCC Upper GI Task Force, by smoothing, simplifying, expanding, and assessing clinical applicability, produced consensus pathologic stage groups. For pT1-3N0M0 squamous cell carcinoma (SCC) and pT1-2N0M0 adenocarcinoma, pT was inadequate for grouping; subcategorizing pT1 and adding histologic grade enhanced staging; cancer location improved SCC staging. Consensus eliminated location for pT2N0M0 and pT3N0M0G1 SCC groups, and despite similar survival, restricted stage 0 to pTis, excluding pT1aN0M0G1. Metastases markedly reduced survival; pT, pN, and pM sufficiently grouped advanced cancers. Stage IIA and IIB had different compositions for SCC and adenocarcinoma, but similar survival. Consensus stage IV subgrouping acknowledged pT4N+ and pN3 cancers had poor survival, similar to pM1. Anatomic pathologic stage grouping, based on pTNM only, produced identical consensus stage groups for SCC and adenocarcinoma at the cost of homogeneity in early groups. Pathologic staging can neither direct pre-treatment decisions nor aid in prognostication for treatment other than esophagectomy or endoscopic therapy. However, it provides a clean, single therapy reference point for esophageal cancer.

KW - epidemiology

KW - esophagectomy

KW - esophagogastric junction

KW - oncology

UR - http://www.scopus.com/inward/record.url?scp=84999750801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999750801&partnerID=8YFLogxK

U2 - 10.1111/dote.12533

DO - 10.1111/dote.12533

M3 - Article

VL - 29

SP - 897

EP - 905

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 8

ER -